KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Accured Expenses (2024 - 2025)

AbCellera Biologics (ABCL) has disclosed Change in Accured Expenses for 2 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 13.21% year-over-year to $5.7 million, compared with a TTM value of $3.5 million through Dec 2025, down 67.49%, and an annual FY2025 reading of $3.5 million, down 67.49% over the prior year.
  • Change in Accured Expenses was $5.7 million for Q4 2025 at AbCellera Biologics, up from $5.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.6 million in Q4 2024 and bottomed at -$4.9 million in Q1 2024.